Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.

Summary

The purpose of this study is to observe the safety and effectiveness of the add-on of intraluminal brachytherapy with BRAXX esophageal brachytherapy applicator after definitive CCRT in patients with thoracic esophageal cancer.

Eligibility

Inclusion Criteria:

* Age of 20-85 years, with ECOG performance 0-2.
* Thoracic esophageal cancer with clinical stage I-IV and biopsy proof; patient with stage I-IV cervical esophageal cancer could be recruited in this trial according to Investigator's assessment.
* Complete CCRT with total doses of 45-55Gy to GTV via external beam radiotherapy (EBRT).

Exclusion Criteria:

* According to Investigator's assessment, patients with double cancer or recurrence could be recruited in this trial if they continue to receive systemic therapy.
* Patient with double cancer, esophageal cancer or recurrence who is scheduled for surgery treatment.
* Involvement of tracheal mucosa or bronchial mucosa.
* Stenosis of esophageal lumen that cannot be bypassed by the applicator after EBRT.
* The distribution of the lesions of interest exceeds 10cm range.
* The patient is participating in other clinical trials.

Conditions10

Browse More Trials